Eighteen months after acquiring a facility in the Czech Republic from Novavax, Novo Nordisk has officially commenced the production of active pharmaceutical ingredients for its next-generation diabetes and obesity treatments. This strategic move underscores the company’s commitment to expanding its manufacturing capabilities in Europe, particularly in response to the increasing global demand for innovative diabetes therapies.
In conjunction with the Czech plant launch, Novo Nordisk has announced a significant $29 million investment aimed at upgrading its manufacturing facility in China. This dual investment reflects the company’s broader strategy to enhance its production infrastructure across key markets, ensuring a robust supply chain for its expanding portfolio of diabetes and obesity medications. As the global diabetes epidemic continues to grow, such investments are critical for maintaining competitive advantage and meeting patient needs effectively.
Open the full market picture for your next decision →
